Sino Biopharmaceutical Limited (SBHMY) Stock

About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories. Among its offerings are oncology treatments, such as Qingkeshu tablets and Leweixin injections; cardiovascular and cerebrovascular medications, including Kaina and Anrixin tablets; hepatitis remedies like Tianqingganmei injections; and orthopedic solutions exemplified by Gaisanchun capsules. The company also produces drugs for respiratory ailments and parenteral nutritional support, for instance, Xinhaineng injections, along with a broad spectrum of other pharmaceutical preparations, such as Tuotuo tablets. Additionally, Sino Biopharmaceutical provides a selection of advanced pharmaceutical agents, including Aprepitant, Lenvatinib Mesilate, Vortioxetine Hydrobromide, and Edaravone injection. Its portfolio also features combination therapies like Amlodipine Besylate and Atorvastatin Calcium, alongside Sofosbuvir, Sitagliptin Phosphate, Colistimethate Sodium for injection, and Tofacitinib Citrate. Beyond its core pharmaceutical manufacturing, the company's diverse business interests encompass property holdings, the retail and distribution of pharmaceutical products, and providing optometry services coupled with the sale of ophthalmic goods. It manages hospitals, delivers medical management and health information consultancy, and offers biotechnology transfer and consultation services. The enterprise is also involved in the production and sale of health foods, provides orthopedic outpatient care and surgical procedures, engages in medical and health technology development, trades optical glasses, and conducts research, development, and commercialization of medical devices and active pharmaceutical ingredients. Established in 2000, the company's corporate headquarters are situated in Wan Chai, Hong Kong.

Sino Biopharmaceutical Limited is headquartered in HK.

Sino Biopharmaceutical Limited (SBHMY) stock trades at $12.68 with a market capitalization of $11.27B. The stock is valued at a price-to-earnings (P/E) ratio of 35.46, price-to-book of 2.71, price-to-sales of 2.58. Over the past 52 weeks the stock has ranged between $11.27 and $20.16, and currently trades 37.1% below its 52-week high. It pays a dividend yielding 1.03%.

On profitability, Sino Biopharmaceutical Limited generates a return on equity (ROE) of 7.32%, return on capital employed of 13.69%, an operating margin of 21.84%, a net profit margin of 7.36%.

Official website: www.sbpgroup.com